Aardvark Therapeutics Inc. Common Stock

AARD | NASDAQ

$5.57

+$0.19 (+3.53%)

At close: Sep 21, 2026, 4:00 PM ET

$5.56

-$0.01 (-0.18%)

After-hours: Sep 21, 2026, 7:54 PM ET

Fiscal Year Period Ending	FY 2025 Dec 30, 2025	FY 2024 Dec 30, 2024	FY 2023 Dec 30, 2023	FY 2022 Dec 30, 2022
Revenue	n/a	n/a	n/a	n/a
Cost of Revenue	n/a	n/a	n/a	n/a
Gross Profit	n/a	n/a	n/a	n/a
Operating Income	-62.73M	-22.79M	-7.42M	-11.36M
Interest Income	5.14M	2.41M	1.42M	120K
Pretax Income	-57.59M	-20.59M	-7.21M	-13.56M
Net Income	-57.59M	-20.59M	-7.21M	-13.56M
Selling & General & Admin	13.79M	5.31M	2.17M	2.7M
Research & Development	48.94M	17.36M	4.48M	7.17M
Other Expenses	n/a	117K	762K	1.49M
Operating Expenses	62.73M	22.79M	7.42M	11.36M
Interest Expense	n/a	n/a	n/a	n/a
Selling & Marketing Expenses	n/a	n/a	n/a	n/a
Cost & Expenses	62.73M	22.79M	7.42M	11.36M
Income Tax Expense	n/a	n/a	n/a	n/a
Shares Outstanding (Basic)	21.82M	21.7M	21.38M	21.38M
Shares Outstanding (Diluted)	21.82M	21.7M	21.38M	21.38M
EPS (Basic)	-2.64	-0.95	-0.34	-0.63
EPS (Diluted)	-2.64	-0.95	-0.34	-0.63
EBITDA	-57.56M	-22.65M	-6.56M	-10.76M
EBIT	-57.59M	-22.67M	-6.65M	-10.87M
Depreciation & Amortization	36K	16K	97K	110K